Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung.

Autor: Dobrzynski JL; University of Iowa Roy J. and Lucille A. Carver College of Medicine, 375 Newton Rd, Iowa City, IA 52242, USA., Vest BE; University of Iowa Hospitals and Clinics, Dermatology, 200 Hawkins Drive, Iowa City, IA 52242, USA., Swick BL; University of Iowa Hospitals and Clinics, Dermatology, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Jazyk: angličtina
Zdroj: Case reports in dermatological medicine [Case Rep Dermatol Med] 2022 Dec 15; Vol. 2022, pp. 5360113. Date of Electronic Publication: 2022 Dec 15 (Print Publication: 2022).
DOI: 10.1155/2022/5360113
Abstrakt: Immune checkpoint inhibitors are associated with a spectrum of cutaneous immune-related adverse events. While maculopapular eruptions are the most common cutaneous adverse event, scleroderma can rarely develop. Herein, we report a case of new-onset scleroderma associated with avelumab treatment in the setting of metastatic squamous cell carcinoma of the lung. The pathophysiology of immune checkpoint inhibitor-induced scleroderma is not completely understood. A proposed mechanism is discussed along with the clinical presentation of symptoms and associated therapeutic response in cancer treatment. This case contributes to the few existing reports of immune checkpoint inhibitor-induced scleroderma to better understand the implications in the management of cutaneous immune-related adverse events.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2022 Jeffrey L. Dobrzynski et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje